The impact of COVID-19 shielding on the wellbeing, mental health and treatment adherence of adults with cystic fibrosis

Article Figures & Data

Table 1.

Anxiety (GAD-7), depression (PHQ-9) and treatment adherence (CFHH) pre- and during the COVID-19 pandemic

Assessment		Pre-COVID	During COVID	Difference
GAD-7 (n=41)	Median [IQR]	2 [0.5–6]	5 [1–11]	+3^*
	Sub-clinical (%)	73	46	–27
	Mild (%)	7.3	27	+20
	Moderate (%)	12	15	+2.4
	Severe (%)	7.3	12	+4.8
	‘Clinical’ (mild-severe; %)	27	54	+27
PHQ-9 (n=43)	Median [IQR]	3 [1–10]	3 [2–12]	0^†
	Sub-Clinical (%)	53	53	0
	Mild (%)	21	16	–4.7
	Moderate (%)	9.3	9.3	0
	Moderate-severe (%)	16	14	–2.3
	Severe (%)	0	7	+7
	‘Clinical’ (mild-severe; %)	47	47	0
CFHH Adherence (n=28) (mean %)		80%	87%	+7%^†

CFHH = cystic fibrosis health hub; GAD-7 = generalised anxiety disorder assessment; IQR = interquartile range; PHQ-9 = patient health depression questionnaire.
↵*Significant (p=0.002);
↵^†not significant.